Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,007 · see citing works

Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics

Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288 · see citing works

Tau in Alzheimer Disease and Related Tauopathies

Iqbal, K., Liu, F., Gong, C., & Grundke, I. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611592 · Cited by 1,122 · see citing works

Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies

Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., Barker, S. J., Foley, A. C., Thorpe, J. R., Serpell, L. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.047 · Cited by 986 · see citing works

tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?

Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works

Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer

Gallien, S., Duriez, E., Crone, C., Kellmann, M., Moehring, T., & Domon, B. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.019802 · Cited by 510 · see citing works

Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.

Clark, L. N., Poorkaj, P., Wszolek, Z., Geschwind, D., Nasreddine, Z. S., Miller, B. L., Li, D., Payami, H., Awert, F., Markopoulou, K., et al. (1998) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.95.22.13103 · Cited by 488 · see citing works

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice

Morris, M., Knudsen, G. M., Maeda, S., Trinidad, J. C., Ioanoviciu, A., Burlingame, A. L., & Mucke, L. (2015) · Nature Neuroscience · doi:10.1038/nn.4067 · Cited by 472 · see citing works

Isotope-labeled Protein Standards

Brun, V., Dupuis, A., Adrait, A., Marcellin, M., Thomas, D. Y., Court, M., Vandenesch, F., & Garin, J. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700163-mcp200 · Cited by 443 · see citing works

Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology

Olsson, A., Vanderstichele, H., Andreasen, N., Meyer, G. D., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 424 · see citing works

A Quantitative Study of the Effects of Chaotropic Agents, Surfactants, and Solvents on the Digestion Efficiency of Human Plasma Proteins by Trypsin

Proc, J. L., Kuzyk, M. A., Hardie, D. B., Yang, J., SMITH, D. S. H., Jackson, A., Parker, C. E., & Borchers, C. H. (2010) · Journal of Proteome Research · doi:10.1021/pr100656u · Cited by 354 · see citing works

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 339 · see citing works

Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300 · see citing works

Neurofibrillary Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration

Sergeant, N., Wattez, A., & Delacourte, A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721243.x · Cited by 287 · see citing works

Does Trypsin Cut Before Proline?

Rodriguez, J., Gupta, N., Smith, R., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0705035 · Cited by 265 · see citing works

Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies

Dujardin, S., Lécolle, K., Caillierez, R., Bégard, S., Zommer, N., Lachaud, C., Carrier, S., Dufour, N., Aurégan, G., Winderickx, J., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-14 · Cited by 259 · see citing works

Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics

Hüttenhain, R., Soste, M., Selevsek, N., Röst, H. L., Sethi, A., Carapito, C., Farrah, T., Deutsch, E. W., Kusebauch, U., Moritz, R. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003989 · Cited by 245 · see citing works

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209 · see citing works

The purification of tau protein and the occurrence of two phosphorylation states of tau in brain.

Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)71345-1 · Cited by 191 · see citing works

Quantification of Axonal Damage in Traumatic Brain Injury

Zemlan, F. P., Rosenberg, W. S., Luebbe, P., Campbell, T. A., Dean, G. E., Weiner, N. E., Cohen, J. A., Rudick, R. A., & Woo, D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720741.x · Cited by 187 · see citing works

Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests

Fortin, T., Salvador, A., Charrier, J., Lenz, C., Lacoux, X., Morla, A., Choquet‐Kastylevsky, G., & Lemoine, J. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800238-mcp200 · Cited by 177 · see citing works

C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death

Kanmert, D., Cantlon, A., Muratore, C., Jin, M., O’Malley, T. T., Lee, G. S., Young‐Pearse, T. L., Selkoe, D. J., & Walsh, D. M. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0387-15.2015 · Cited by 159 · see citing works

The importance of the digest: Proteolysis and absolute quantification in proteomics

Brownridge, P., & Beynon, R. J. (2011) · Methods · doi:10.1016/j.ymeth.2011.05.005 · Cited by 152 · see citing works

Selectivity of LC-MS/MS analysis: Implication for proteomics experiments

Gallien, S., Duriez, E., Demeure, K., & Domon, B. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.11.005 · Cited by 147 · see citing works

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 146 · see citing works

Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility

Percy, A. J., Chambers, A. G., Yang, J., Hardie, D. B., & Borchers, C. H. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.06.008 · Cited by 145 · see citing works

Role of the Tau N-terminal region in microtubule stabilization revealed by newendogenous truncated forms

Derisbourg, M. J., Leghay, C., Chiappetta, G., Fernández-Gómez, F.-J., Laurent, C., Demeyer, D., Carrier, S., Buée‐Scherrer, V., Blum, D. L., Vinh, J., et al. (2015) · Scientific Reports · doi:10.1038/srep09659 · Cited by 133 · see citing works

Divergent CSF   alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308004 · Cited by 132 · see citing works

Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry

Lame, M. E., Chambers, E. E., & Blatnik, M. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.08.010 · Cited by 123 · see citing works

Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach

Thomas, S. N., Funk, K. E., Wan, Y., Liao, Z., Davies, P., Kuret, J., & Yang, A. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0893-0 · Cited by 123 · see citing works

Rapid empirical discovery of optimal peptides for targeted proteomics

Stergachis, A. B., MacLean, B., Lee, K., Stamatoyannopoulos, J. A., & MacCoss, M. J. (2011) · Nature Methods · doi:10.1038/nmeth.1770 · Cited by 110 · see citing works

The emergence of top-down proteomics in clinical research

Savaryn, J. P., Catherman, A. D., Thomas, P. M., Abecassis, M. M., & Kelleher, N. L. (2013) · Genome Medicine · doi:10.1186/gm457 · Cited by 103 · see citing works

Total ApoE and ApoE4 Isoform Assays in an Alzheimer's Disease Case-control Study by Targeted Mass Spectrometry (n = 669): A Pilot Assay for Methionine-containing Proteotypic Peptides

Simon, R., Girod, M., Fonbonne, C., Salvador, A., Clément, Y., Lantéri, P., Amouyel, P., Lambert, J. C., & Lemoine, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018861 · Cited by 92 · see citing works

Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry

Portelius, E., Hansson, S., Tran, A. J., Zetterberg, H., Grognet, P., Vanmechelen, E., Höglund, K., Brinkmalm, G., Brinkmalm, A., Nordhoff, E., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr7008669 · Cited by 79 · see citing works

PSAQ™ standards for accurate MS–based quantification of proteins: from the concept to biomedical applications

Picard, G., Lebert, D., Louwagie, M., Adrait, A., Huillet, C., Vandenesch, F., Bruley, C., Garin, J., Jaquinod, M., & Brun, V. (2012) · Journal of Mass Spectrometry · doi:10.1002/jms.3106 · Cited by 79 · see citing works

Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry

McAvoy, T., Lassman, M. E., Spellman, D. S., Ke, Z., Howell, B. J., Wong, O., Lan, Z., Tanen, M. R. L., Struyk, A. F., & Laterza, O. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.216515 · Cited by 75 · see citing works

Proline‐Directed Random‐Coil Chemical Shift Values as a Tool for the NMR Assignment of the Tau Phosphorylation Sites

Lippens, G. M., Wieruszeski, J., Leroy, A., Smet‐Nocca, C., Sillen, A., Buée, L., & Landrieu, I. (2003) · ChemBioChem · doi:10.1002/cbic.200300763 · Cited by 65 · see citing works

Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease

Hanger, D. P., Lau, D. H. W., Phillips, E. C., Bondulich, M. K., Guo, T., Woodward, B. W., Pooler, A. M., & Noble, W. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132054 · Cited by 62 · see citing works

Mild Performic Acid Oxidation Enhances Chromatographic and Top Down Mass Spectrometric Analyses of Histones*S

Pesavento, J. J., Garcia, B., Streeky, J. A., Kelleher, N., & Mizzen, C. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600404-mcp200 · Cited by 61 · see citing works

Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study

Gabelle, A., Dumurgier, J., Vercruysse, O., Paquet, C., Bombois, S., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Buée, L., Pasquier, F., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121549 · Cited by 60 · see citing works

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry

Bros, P., Vialaret, J., Barthélemy, N. R., Delatour, V., Gabelle, A., Lehmann, S., & Hirtz, C. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00302 · Cited by 45 · see citing works

Mass spectrometry‐based absolute protein quantification: PSAQ ™ strategy makes use of “noncanonical” proteotypic peptides

Jaquinod, M., Trauchessec, M., Huillet, C., Louwagie, M., Lebert, D., Picard, G., Adrait, A., Dupuis, A., Garin, J., Brun, V., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201100538 · Cited by 27 · see citing works

Detection of tau forms in CSF requires sensitive techniques

Kuiperij, H. B., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.013 · Cited by 10 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651 · see citing works

Tau Kinetics in Neurons and the Human Central Nervous System

Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437 · see citing works

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works

Tau-targeting therapies for Alzheimer disease: Current status and future directions

Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371 · see citing works

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease

Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., Koertvelyessy, P., Bittner, D., Schipke, C. G., Incesoy, E. I., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199356 · Cited by 286 · see citing works

Tau deletion promotes brain insulin resistance

Marciniak, E., Leboucher, A., Caron, E., Ahmed, T., Tailleux, A., Dumont, J., Issad, T., Gerhardt, E., Pagesy, P., Vileno, M., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161731 · Cited by 205 · see citing works

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease

Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · see citing works

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168 · see citing works

Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers

Quinn, J. P., Corbett, N. J., Kellett, K. A. B., & Hooper, N. M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170959 · Cited by 170 · see citing works

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease

Barthélemy, N. R., Mallipeddi, N., Moiseyev, P., Sato, C., & Bateman, R. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00121 · Cited by 152 · see citing works

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease

Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153 · see citing works

Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

Nobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120 · see citing works

A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease

Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111 · see citing works

Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo

DeVos, S. L., Corjuc, B. T., Commins, C., Dujardin, S., Bannon, R. N., Corjuc, D., Moore, B. D., Bennett, R. E., Jorfi, M., Gonzales, J. A., et al. (2018) · Brain · doi:10.1093/brain/awy117 · Cited by 106 · see citing works

Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease

Zhou, M., Haque, R. U., Dammer, E. B., Duong, D. M., Ping, L., Johnson, E. C. B., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09285-8 · Cited by 92 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works

Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF

Hitt, B. D., Vaquer-Alicea, J., Manon, V. A., Beaver, J. D., Kashmer, O. M., Garcia, J. N., & Diamond, M. I. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01185-8 · Cited by 71 · see citing works

Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression

Chen, H.-H., Liu, P., Auger, P., Lee, S.-H., Adolfsson, O., Rey-Bellet, L., Lafrance-Vanasse, J., Friedman, B. A., Pihlgren, M., Muhs, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35130-y · Cited by 51 · see citing works

Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease

Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37 · see citing works

Progress in the proteomics research of cerebrospinal fluid

Cai, Y., & Liu, Y. (2017) · Zhonghua jianyan yixue zazhi · doi:10.3760/cma.j.issn.1009-9158.2017.12.005

Application of quantitative proteomics in understanding cellular functions in prokaryotes

Tv, A., & Naitam, M. G. (2019) · Journal of Pharmacognosy and Phytochemistry

Quantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers

Masuda, T., Mori, A., Ito, S., & Ohtsuki, S. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.09.006 · Cited by 39 · see citing works

Quantitative plant proteomics

Bindschedler, L. V., & Cramer, R. (2010) · PROTEOMICS · doi:10.1002/pmic.201000426 · Cited by 80 · see citing works

Advancements in Bio-Mass Spectrometry Based Quantitative Proteomics

Zhang, L. (2014) · Cited by 1 · see citing works